

Cytoreductive nephrectomy and exposure to sunitinib – a post-hoc analysis of the SURTIME trial

Yasmin Abu-Ghanem¹, Johannes V van Thienen², Christian Blank², Maureen J.B. Aarts³, Michael Jewett⁴, Igle Jan de Jong⁵, J.B. Lattouf⁶, Harm H.E. van Melick⁷, Lori Wood⁸, Peter Mulders⁹, Sylvie Rottey¹⁰, John Wagstaff¹¹, Patricia Zondervan¹², Tom Powles¹³, Anouk Neven¹⁴, Laurence Collette¹⁴, Bertrand Tombal^{14,15}, John Haanen², Axel Bex^{1,2}

¹Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London

²Netherlands Cancer Institute, Amsterdam

³Maastricht University Medical Center, Maastricht

⁴Princess Margaret Hospital, Toronto

⁵University of Groningen, University Medical Center Groningen

⁶University of Montreal Hospital Center, Montreal.

⁷Saint Antonius Hospital, Nieuwegein

⁸QEII Health Sciences Center, Halifax

⁹Radboud University Hospital, Nijmegen

¹⁰Ghent University Hospital, Ghent

¹¹South West Wales Cancer Centre and Swansea University College of Medicine

¹²University Medical Centers, Amsterdam

¹³Barts and Queen Mary University London

¹⁴European Organisation of Research and Treatment of Cancer (EORTC), Brussels

¹⁵Cliniques Universitaires Saint-Luc, Brussels

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/BJU.15625](#)

This article is protected by copyright. All rights reserved

Running head: Exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy

Keyword: cytoreductive nephrectomy, deferred, immediate, renal cell carcinoma, sunitinib, survival

Word count of the text: 2027

Corresponding author: Prof Axel Bex.

Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London; Netherlands Cancer Institute, Amsterdam.

Tel: +44 020 7794 0500

Fax: +44 020 7472 6728

E-mail: axel.bex@nhs.net

DR. YASMIN ABU-GHANEM (Orcid ID : 0000-0003-3682-5963)

PROF. BERTRAND TOMBAL (Orcid ID : 0000-0002-0093-8408)

Article type : Original Article

Cytoreductive nephrectomy and exposure to sunitinib – a post-hoc analysis of the SURTIME trial

Yasmin Abu-Ghanem¹, Johannes V van Thienen², Christian Blank², Maureen J.B. Aarts³, Michael Jewett⁴, Igle Jan de Jong⁵, J.B. Lattouf⁶, Harm H.E. van Melick⁷, Lori Wood⁸, Peter Mulders⁹, Sylvie Rottey¹⁰, John Wagstaff¹¹, Patricia Zondervan¹², Tom Powles¹³, Anouk Neven¹⁴, Laurence Collette¹⁴, Bertrand Tombal^{14,15}, John Haanen², Axel Bex^{1,2}

¹Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London

²Netherlands Cancer Institute, Amsterdam

³Maastricht University Medical Center, Maastricht

⁴Princess Margaret Hospital, Toronto

⁵University of Groningen, University Medical Center Groningen

⁶University of Montreal Hospital Center, Montreal.

⁷Saint Antonius Hospital, Nieuwegein

⁸QEII Health Sciences Center, Halifax

⁹Radboud University Hospital, Nijmegen

¹⁰Ghent University Hospital, Ghent

¹¹South West Wales Cancer Centre and Swansea University College of Medicine

¹²University Medical Centers, Amsterdam

¹³Barts and Queen Mary University London

¹⁴European Organisation of Research and Treatment of Cancer (EORTC), Brussels

¹⁵Cliniques Universitaires Saint-Luc, Brussels

Running head: Exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy

Keyword: cytoreductive nephrectomy, deferred, immediate, renal cell carcinoma, sunitinib, survival

Word count of the text: 2050

Corresponding author: Prof Axel Bex.

Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London; Netherlands Cancer Institute, Amsterdam.

Tel: +44 020 7794 0500

Fax: +44 020 7472 6728

E-mail: axel.bex@nhs.net

Abstract

Objective: To analyze if exposure to sunitinib in the SURTIME trial which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy is associated with the overall survival (OS) benefit observed in the deferred CN arm.

Subjects and Methods: A post-hoc analysis of SURTIME trial data. Variables analysed included number of patients receiving sunitinib, time from randomisation to start sunitinib, overall response rate (ORR) by RECIST 1.1, and duration of drug exposure and dose in the intention-to-treat population of the immediate and deferred arm. Descriptive methods and 95% confidence-intervals (CI) were used.

Results: In the deferred arm, 97.7%(CI:89.3-99.6; n=48) received sunitinib versus 80% (CI:66.9-88.7,n=40) in the immediate arm. Following immediate CN, 19.6% progressed 4 weeks after CN and median time to start sunitinib was 39.5 days versus 4.5 days in the deferred arm. At week 16, 46.0% had progressed at metastatic sites in the immediate CN arm versus 32.7% in the deferred arm. Sunitinib dose reductions, escalations and interruptions were not statistically significantly different between arms. Among patients who received sunitinib in the immediate or deferred arm the median total sunitinib treatment duration was 172.5 versus 248 days. Reduction of target lesions was more profound in the deferred arm.

Conclusions: In comparison to the deferred CN approach, immediate CN impairs administration, onset, and duration of sunitinib. Starting with systemic therapy leads to early and more profound disease control and identification of progression prior to planned CN which may have contributed to the observed OS benefit.

Introduction

Renal cell carcinoma (RCC) accounts for 3-5% of all adult tumours and is the seventh most common in men and eighth among women [1]. Despite nephrectomy with curative intent, approximately 15-20% of patients are metastatic at the time of diagnosis and 20-40% are expected to develop post-operative metastases [2].

In the cytokine era, cytoreductive nephrectomy (CN) has become the standard treatment in selected patients on the basis of two prospective, randomised studies [3],

[4]. However, this standard has lately been re-challenged by the CARMENA (The Clinical Trial to Assess the Importance of Nephrectomy) trial [5] in which patients were randomized to receive either vascular endothelial growth factor receptor (VEGFR)-targeted therapy with sunitinib alone or the former standard of upfront CN followed by sunitinib. Ultimately, median overall survival (OS) with sunitinib alone was non-inferior to the upfront CN approach followed by sunitinib but deferred CN was an option in the sunitinib only arm and performed in 17% of the patients. The concept of deferred CN was investigated in the SURTIME (Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients with Metastatic Kidney Cancer) trial [6]. In which metastatic RCC (mRCC) patients were randomised to sunitinib therapy first, followed by CN in the absence of progression versus immediate CN followed by sunitinib. The study results were mainly exploratory due to poor accrual, but suggested that with the deferred approach, patients were more likely to receive sunitinib and had better OS results. Endpoints were previously reported [6]. The hazard ratio of the secondary endpoint OS favored deferred CN [0.57(CI: 0.34–0.95,p=0.032)] with a median OS of 32.4 versus only 15.0 months following immediate CN. The conclusion by the authors was that pre-treatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN and avoid an unnecessary intervention [7]. In accordance with the recent studies[8], the EAU RCC guidelines have responded to this paradigm change [9] and recommend systemic therapy for patients with primary mRCC and progressive metastatic disease with the option to consider deferred CN in those responding at metastatic sites. Here, we investigated in a post-hoc analysis of SURTIME data if differences in the exposure to sunitinib in the study arms occurred which may be associated with the survival benefit observed after upfront systemic therapy followed by deferred CN compared to immediate CN followed by sunitinib in the postoperative setting.

Methods

The current study is a post hoc analysis of the SURTIME clinical trial [7]. SURTIME was designed as a randomized phase III trial comparing deferred to immediate CN in patients with clear-cell mRCC treated by sunitinib. The primary end-point was progression free survival in the intention-to-treat population. Patients were recruited to the trial from July 2010, to March 2016 according to pre-defined eligibility criteria. Patients were randomized 1:1 at the EORTC to immediate CN followed by sunitinib therapy vs treatment of sunitinib (3 cycles) followed by CN and sunitinib. In case of systemic progressive disease (PD) in the deferred arm, nephrectomy was not recommended but left at the discretion of each investigator. In both arms a per-protocol rest period of 4 weeks following CN was scheduled to allow for recovery from surgery. Sunitinib was started at 50 mg/ day 4 weeks on/2 weeks off followed by dose reductions by increments of 12.5 mg in case of treatment related adverse events and administered until disease progression or unmanageable toxicity. Dose interruptions were allowed. The study was approved by the institutional review board at each centre included. All patients signed written informed consent forms, and all data were deidentified [7].

Outcomes

The primary aim of this post-hoc analysis is to assess exposure to sunitinib defined by number of individuals treated with the study drug, the length of treatment period and dose reductions and modifications. Duration of sunitinib exposure for patients in the immediate CN arm include the time from start sunitinib after a per-protocol recovery period of 4 weeks following CN until discontinuation. In the deferred arm the duration is

assessed from sunitinib start until discontinuation taking into account the 4-week per-protocol interruption of sunitinib for surgery (i.e. sum of pre-surgery and post-surgery treatment period). The secondary aim is to assess the treatment response in the sum of target lesions (including the primary tumour and distant metastatic sites) according to RECIST 1.1 in both arms over time.

Inclusion and exclusion criteria

The study included patients > 18 years with histologically proven, previously untreated clear cell mRCC with an asymptomatic resectable primary tumor, eligible to therapy with sunitinib. Further requirements included a World Health Organization (WHO) performance status of 0-1; measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; life expectancy greater than 3 months; adequate bone marrow, liver, cardiac, and renal function. Exclusion criteria included clinical signs of central nervous system involvement; 3 or more surgical risk factors including serum albumin according to Common Terminology Criteria For Adverse Events (CTCAE), version 4.0 grade 2 or higher, serum lactate dehydrogenase (LDH) > 1.5 times the upper limit of normal, liver metastases, symptomatic metastases, retroperitoneal or supradiaphragmatic lymph node involvement, and stage cT3-T4 disease [7].

Analysis methods:

Reasons for dose reductions, modifications and discontinuation (progression, toxicity) were collected and the sequence and duration of study treatment (sunitinib, CN, second line therapies) were illustrated as swimmer plots. We used spider plots to illustrate the combined response of sunitinib and CN on the sum of the longest diameter of all target lesions (according to RECIST 1.1) including the primary tumour and metastatic sites in both pre-specified treatment groups over time. Confidence intervals (CI) are presented at the 95% confidence level.

Results:

A total of 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years) were randomized, 50 in the immediate CN arm and 49 in the deferred CN arm [1]. Patient characteristics are displayed in Table 1.

In the deferred CN arm, 97.7% (CI: 89.3-99.6; n=48) received sunitinib versus only 80% (CI: 66.9-88.7, n=40) in the immediate CN arm (Table 2). In the deferred CN arm, 48 patients started on sunitinib at a median of 4.5 days after randomisation and had a total duration of sunitinib exposure of 248 days, corrected for the per-protocol 4 week recovery time for those patients following deferred CN. Postoperative sunitinib was continued in 29 of the 40 patients who underwent CN in the deferred arm, 6 of whom despite progression at metastatic sites. Following immediate CN, 40 of 50 patients (80%) started on trial drug with a median time of 39.5 days after randomisation. This includes the per-protocol 4-week recovery period from CN at the end of which 19.6% had confirmed RECIST progression at a pre-planned interval CT scan to assess the progression rate following CN prior to start of systemic therapy. In addition, 25% started

with sunitinib beyond the 4 week recovery period after surgery. The median total duration of sunitinib exposure in the immediate CN arm was 172.5 days.

Of those who received systemic therapy in the deferred and immediate arm, 41.7% (20/48) and 32.5% (13/40) experienced dose reduction, respectively, among other dose modification (Table 3). Of the 20 patients in the deferred arm, 14 reduced to 37.5 mg, 5 to 25 mg and 1 to 12.5 mg. Similar rates were observed in the immediate arm as 11 of 13 reduced to 37.5 mg and 2 to 12.5 mg (Table 3).

At week 16, 46.0% (23/50) had progressed at metastatic sites in the immediate CN arm versus 32.7% (16/49) in the deferred arm. An overview of treatment received (surgery / sunitinib) and timing are given in Figure 1. In both arms, the major reason for sunitinib discontinuation was disease progression (figure 1). In the deferred and immediate arm only 2 and 4 patients discontinued sunitinib after surgery because of adverse events, respectively.

Regarding target lesions, both arms had a comparable size of target lesions and primary tumors prior to therapy (table 1). Reduction of all target lesions over time was more profound in the deferred arm (Figure 2).

Discussion:

In the current post hoc analysis, fewer patients received systemic therapy in the immediate CN arm, which was administered later and shorter compared to the deferred approach. Moreover, the decrease in the sum of target lesions over time was more profound in the deferred CN arm. In the SURTIME clinical trial, deferred CN in patients with mRCC did not improve the rate of progression free survival at 28 weeks. However, the deferred CN approach resulted in favourable OS, which was a secondary endpoint [7]. These findings are supported by several retrospective studies including a high number of patients which suggest that deferred CN is associated with improved OS compared to immediate CN [10][11]. In support of these findings, a recent retrospective study by Bhindi et al, reported that sunitinib followed by deferred CN was associated with improved OS and time to sunitinib treatment failure [12]. Also, patients who underwent deferred CN after upfront targeted therapy (TT) had improved OS at 3 and 6-month compared to those who received TT alone [13][14]. It needs to be acknowledged, however, that these retrospective real-world data are limited by selection bias. Therefore it is interesting that in the prospective CARMENA trial, in the sunitinib-alone arm, secondary nephrectomy was also associated with improved OS compared with no nephrectomy [5]. These results may support the role of deferred CN in some mRCC patients, yet, the optimal timing and indication remains to be defined. In the current analysis, we found that the concept of immediate systemic therapy followed by deferred CN in the absence of disease progression is associated with earlier and longer TT treatment. Further, there is a more profound control of the disease, which may have contributed to the difference in OS between the two groups. Interestingly, it has been suggested that one of the major concerns regarding the immediate CN approach is the risk of not receiving subsequent systemic therapy in up to 30% of patients, mainly due to rapid disease progression or postoperative complications [15]. And indeed, in SURTIME, after immediate CN fewer patients received systemic treatment and for a shorter period.

Immediate systemic therapy is now recommended for patients with poor performance status or high metastatic burden in association with intermediate and poor prognosis as no benefit has been shown for CN in this setting [5], [16], [17]. Also, immediate systemic therapy could serve as a litmus test to decide about subsequent CN [18], [19]. Upfront systemic therapy with VEGFR-TT potentially distinguishes between patients with an aggressive tumour biology who are unlikely to benefit from CN, and those with mainly angiogenesis-driven tumours who undergo deferred CN as a consequence of a favorable disease biology. As seen in the current post-hoc analysis of SURTIME, these patients have better OS and are treated longer with the VEGFR-tyrosine kinase inhibitor sunitinib. Meanwhile sunitinib has been replaced by several immune checkpoint inhibitor (ICI) combination therapies including monoclonal antibodies directed against the programmed death receptor 1 (PD-1) or its ligand (PDL-1) in combination with either monoclonal antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or vascular endothelial growth factor receptor (VEGFR) inhibitors as standard of care in treatment-naïve clear-cell RCC [20], [21]. Nevertheless, control of the disease in patients who require systemic therapy by administering drug treatment first rather than surgery first may be a universal concept and a legacy from CARMENA and SURTIME. This is reflected in the fact that in all pivotal ICI combination phase 3 trials 16-30% of the included mRCC patients had unresected primary tumours and were treated with acceptable safety and favorable outcome in exploratory subgroup analyses compared to sunitinib [22]. Complete pathological responses have been described in 10% of these patients [23], [24] and increasingly patients with near complete response are offered deferred CN. This concept is currently not supported by prospective data but randomised controlled trials investigating deferred CN in the era of immune checkpoint inhibitor combination therapy have started accrual (NCT03977571 and NCT04510597).

Strengths of our study include the use of randomized trial data. Furthermore, availability of data on duration of treatment and response in target lesions allowed for more thorough comparison between groups. Limitation include accrual limitation as previously described [7] as well as the nature of a post hoc analysis of the data.

In conclusion, our data support the use of upfront systemic therapy in patients with primary mRCC. This allows more patients to receive a longer duration of systemic therapy. Time on systemic therapy is associated with a greater reduction in tumor burden and prolonged OS. In comparison, immediate CN impairs early onset of systemic therapy with control of the disease in fewer patients.

Acknowledgments:

We thank the following contributors to the SURTIME trial:

Maria del Pilar Laguna (Istanbul Medipol University, Turkey), Patricia Soetekouw (University Medical Center Nijmegen, Netherlands), Sandrine Marreaud (EORTC), Roland van Velthoven (Institut Jules Bordet, Brussels)

Source of funding

The study was supported by a restricted educational grant from Pfizer. This publication was also supported by a donation from the Kankerbestrijding/KWF from The Netherlands through the EORTC Cancer Research Fund

Conflicts of Interest

None declared

References

- [1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, "Cancer statistics, 2009.," *CA. Cancer J. Clin.*, vol. 59, no. 4, pp. 225–49, Jul. 2009, doi: 10.3322/caac.20006.
- [2] A. I. Chin, J. S. Lam, R. A. Figlin, and A. S. Belldegrun, "Surveillance strategies for renal cell carcinoma patients following nephrectomy.," *Rev. Urol.*, vol. 8, no. 1, pp. 1–7, 2006.
- [3] G. H. J. Mickisch, A. Garin, H. Van Poppel, L. De Pijck, and R. Sylvester, "Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial," *Lancet*, vol. 358, no. 9286, pp. 966–970, Sep. 2001, doi: 10.1016/S0140-6736(01)06103-7.
- [4] R. C. Flanigan *et al.*, "Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer," *N. Engl. J. Med.*, vol. 345, no. 23, pp. 1655–1659, Dec. 2001, doi: 10.1056/NEJMoa003013.
- [5] A. Méjean *et al.*, "Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma," <https://doi.org/10.1056/NEJMoa1803675>, vol. 379, no. 5, pp. 417–427, Jun. 2018, doi: 10.1056/NEJMOA1803675.
- [6] A. Bex *et al.*, "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial," *JAMA Oncol.*, vol. 5, no. 2, pp. 164–170, 2019, doi: 10.1001/jamaoncol.2018.5543.
- [7] A. Bex *et al.*, "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving

Sunitinib: The SURTIME Randomized Clinical Trial,” *JAMA Oncol.*, vol. 5, no. 2, pp. 164–170, 2019, doi: 10.1001/jamaoncol.2018.5543.

- [8] B. Bhindi *et al.*, “Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma,” *J. Urol.*, vol. 200, no. 3, pp. 528–534, 2018, doi: 10.1016/j.juro.2018.03.077.
- [9] A. Bex *et al.*, “Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma,” *Eur. Urol.*, vol. 74, no. 6, pp. 805–809, Dec. 2018, doi: 10.1016/J.EURURO.2018.08.008.
- [10] N. Hanna *et al.*, “Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study,” *J. Clin. Oncol.*, vol. 34, no. 27, pp. 3267–3275, Sep. 2016, doi: 10.1200/JCO.2016.66.7931.
- [11] R. de Bruijn *et al.*, “Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data,” *Eur. Urol. Oncol.*, vol. 3, no. 2, pp. 168–173, 2020, doi: 10.1016/j.euo.2019.12.004.
- [12] B. Bhindi *et al.*, “Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma,” *Eur. Urol.*, 2020, doi: 10.1016/j.eururo.2020.04.038.
- [13] B. Bhindi *et al.*, “Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma,” *J. Urol.*, vol. 200, no. 3, pp. 528–534, Sep. 2018, doi: 10.1016/j.juro.2018.03.077.
- [14] R. de Bruijn *et al.*, “Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data,” *Eur. Urol. Oncol.*, vol. 3, no. 2, pp. 168–173, Apr. 2020,

doi: 10.1016/j.euo.2019.12.004.

- [15] B. Bhindi *et al.*, “Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma,” *European Urology*, vol. 75, no. 1. Elsevier B.V., pp. 111–128, 01-Jan-2019, doi: 10.1016/j.eururo.2018.09.016.
- [16] R. Mathieu *et al.*, “Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features,” *Urol. Oncol. Semin. Orig. Investig.*, vol. 33, no. 8, pp. 339.e9-339.e15, Aug. 2015, doi: 10.1016/j.urolonc.2015.05.014.
- [17] D. Y. C. Heng *et al.*, “Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium,” *Eur. Urol.*, vol. 66, no. 4, pp. 704–710, Oct. 2014, doi: 10.1016/j.eururo.2014.05.034.
- [18] T. Powles *et al.*, “The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer,” *Eur. Urol.*, vol. 60, no. 3, pp. 448–454, Sep. 2011, doi: 10.1016/j.eururo.2011.05.028.
- [19] T. Powles *et al.*, “Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer,” *JAMA Oncol.*, vol. 2, no. 10, pp. 1303–1309, Oct. 2016, doi: 10.1001/jamaoncol.2016.1197.
- [20] J. Bedke *et al.*, “Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma,” *Eur. Urol.*, vol. 79, no. 3, pp. 339–342, Mar. 2021, doi: 10.1016/j.eururo.2020.12.005.
- [21] B. Ljungberg *et al.*, “EAU guidelines on renal cell carcinoma,” *Eur. Assoc. Urol.*, pp. 1–84, 2021.
- [22] T. Kuusk, Y. Abu-Ghanem, F. Mumtaz, T. Powles, and A. Bex, “Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy,” *Curr.*

Opin. Urol., vol. 31, no. 3, pp. 262–269, May 2021, doi: 10.1097/MOU.0000000000000868.

- [23] N. Singla *et al.*, “Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma,” *Urol. Oncol. Semin. Orig. Investig.*, vol. 37, no. 12, pp. 924–931, Dec. 2019, doi: 10.1016/j.urolonc.2019.08.012.
- [24] N. Singla *et al.*, “Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database,” *Urol. Oncol. Semin. Orig. Investig.*, vol. 38, no. 6, pp. 604.e9-604.e17, Jun. 2020, doi: 10.1016/j.urolonc.2020.02.029.

Table 1: Baseline characteristics

No. (%)	Assigned to immediate nephrectomy (N=50)	Assigned to deferred nephrectomy (N=49)	All randomized patients (N=99)
Age (years):			
Median (range)	60 (39-78)	58 (43-74)	59 (39-78)
Gender:			
Male	41 (82.0)	39 (79.6)	80 (80.8)
Female	9 (18.0)	10 (20.4)	19 (19.2)
WHO performance status:			
0	36 (72.0)	31 (63.3)	67 (67.7)
1	14 (28.0)	18 (36.7)	32 (32.3)
Primary tumor size (mm):			
Mean+SD, median (Range)	93.1+37.8 91 (13-200)	96.8+31.3 96 (33-180)	95.0+34.6 94.5 (13-200)
Sum of all target lesions at entry (mm)			
Mean+SD, median (Range)	169.7+71.9 162 (48-419)	159.2+46.7 162 (45-244)	164.5+60.5 162 (45-419)
Number of surgical risk factors ^a :			
0	8 (16.0)	11 (22.4)	19 (19.2)
1	14 (28.0)	16 (32.7)	30 (30.3)
2	16 (32.0)	15 (30.6)	31 (31.3)
3	12 (24.0)	7 (14.3)	19 (19.2)
Clinical T stage ^b :			
T1	9 (18.0)	8 (16.3)	17 (17.2)
T2	15 (30.0)	23 (46.9)	38 (38.4)
T3	22 (44.0)	15 (30.6)	37 (37.4)
T4	4 (8.0)	3 (6.1)	7 (7.1)

Clinical N stage ^b :			
N0	17 (34.0)	20 (40.8)	37 (37.4)
N1	15 (30.0)	10 (20.4)	25 (25.3)
N2	10 (20.0)	8 (16.3)	18 (18.2)
Unknown	8 (16.0)	11 (22.5)	19 (19.1)
MSKCC risk score ^c :			
Intermediate risk (1-2 factors)	43 (86.0)	44 (89.8)	87 (87.9)
Poor risk (3 factors)	7 (14.0)	5 (10.2)	12 (12.1)

^a Surgical risk factors include serum albumin < 3 g/dl, serum LDH > 1.5 x ULN, liver metastases, symptoms at presentation due to metastases, retroperitoneal lymph node involvement, supra-diaphragmatic lymph node involvement, clinical stage T3 or T4.

^b clinical T stage and clinical N stage according to TNM classification, seventh edition (2009) ^c MSKCC score for metastatic renal cell carcinoma include time from diagnosis to systemic treatment <1 year (replaced by the time between first diagnosis of metastatic RCC and randomization), hemoglobin < LLN (13.5g/dl for men, 12.0 g/dl for women), calcium >10mg/dl (>2.5 mmol/L), serum LDH > 1.5 x ULN, Karnofsky Performance status <80% (replaced by WHO performance status ≥2).

Table 2: Treatment duration of Sunitinib for patients who started on study drug in both arms (days)

	Immediate (N=50)	Deferred (N=49)
Patients who started on sunitinib (number, percent and 95% confidence interval)	40 80% (CI: 66.9-88.7)	48 97.7% (CI: 89.3-99.6)
Total duration of sunitinib exposure (pre and post-surgery) (in days) – taking into account the interruption of sunitinib for surgery in the deferred arm (i.e. sum of pre-surgery and post-surgery treatment period)		
Median	172.5	248.0
Range	4.0 - 1744.0	17.0 - 1623.0

Time from randomization to sunitinib start (in days)		
Median	39.5	4.5
Range	31.0 - 85.0	1.0 - 15.0
Interruption of sunitinib for surgery in the experimental arm (in days)		
Median	-	37.0
Range	-	22.0-75.0
N obs	-	30

Table 3: Dose modification sunitinib treatment

Total sunitinib treatment – subset of patients who received sunitinib (pre- and/or post-operative trt)		
Dose modifications (pre- and/or post-operative trt)	Immediate (N=40)	Deferred (N=48)
Dose reduction No of patients (%)	13 (32.5)	20 (41.7)
95% Confidence interval on percent	(18.6 - 49.1)	(27.6 – 56.8)
Dose escalation	1 (2.5)	2 (4.2)

95% Confidence interval	(0.00 – 0.13)	(0.01 – 0.14)
Dose interruption	10 (25.0)	17 (35.4)
95% Confidence interval	(12.7 – 41.2)	(22.1 – 50.5)
Dose reduction – subset of patients with a dose reduction by 12.5 mg increments (pre- and/or post-operative trt)		
Dose reduction (pre- and/or post-operative trt)	Immediate (N=13)	Deferred (N=20)
Lowest dose level reached		
37.5 mg/day	11 (84.6)	14 (70.0)
25 mg/day	2 (15.4)	5 (25.0)
12.5 mg/day	0 (0.0)	1 (5.0)

Figure 1: Overview of events immediate vs deferred arms; a- immediate arm, b- deferred arm





Figure 2: Target lesions measurements immediate vs deferred arms;



Time since treatment start (weeks); Negative numbers indicate baseline tumour burden assessment prior to start of treatment as was the case in this trial; Grey bars show progression status assessment at week 16 and 28 in accordance with trial methods;